The Egret strategy for drug development is based on its Global Alliance Drug Discovery Platform (GADDP). This platform is designed to take advantage of the abundance of talent in China, and the experience and resource management practices of multinational drug companies. Through partnership with US pharmaceutical companies and academic research institutes, Egret stays current with newly introduced drug discovery and development technologies. We have the ability to evaluate and license research programs that appear attractive for further development in East Asian markets.

Egret's international network, and its commitment to the creation of a sustainable infrastructure, as well as its desire to collaborate with the top research institutes in China, is a key element of its Egret’s strategic differentiation.

At egret, Egret's R&D teams include the Chemistry Department, Analytical Department, Biology and Preclinical Pharmacology Department, Clinical Research Department and Regulatory Affairs Department.